Galera Therapeutics

Developing novel therapeutics with the potential to transform radiotherapy in cancer

Galera is focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. The company’s lead candidate is avasopasem manganese (GC4419), a highly selective small molecule superoxide dismutase (SOD) mimetic initially being developed for the reduction of radiation-induced severe oral mucositis (SOM).

Status
NASDAQ: GRTX
Year of Investment
2020
Strategy
Life Sciences
Location
Malvern, Pennsylvania